Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder

Trial Profile

Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs Nemorexant (Primary)
  • Indications Insomnia
  • Focus Registrational; Therapeutic Use
  • Sponsors Idorsia Pharmaceuticals
  • Most Recent Events

    • 07 Feb 2019 According to the Idorsia Pharmaceuticals media release, data from this trial is expected in the first half of 2020.
    • 24 Jan 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Oct 2019.
    • 11 Jun 2018 Status changed from not yet recruiting to recruiting, according to Idorsia Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top